PBAC Public Summary Documents (first time rejections and deferrals) - March 2019 meeting

19 July 2019 - The Public Summary Documents (first time rejections and deferrals) from the March 2019 PBAC meeting are now ...

Read more →

Evaluation of ethical analyses in seven reports from the European Network for Health Technology Assessment

16 July 2019 - Ethics has been considered among the core domains of health technology assessment, but there are still ...

Read more →

Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund

17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...

Read more →

Implementation of “coverage with evidence development” drug approval strategies found lacking

15 July 2019 - Lessons from early deployments in The Netherlands. ...

Read more →

NICE recommends Skyrizi, Forxiga

15 July 2019 - NICE has recommended two new drugs on the NHS, AbbVie’s Skyrizi (risankizumab) and AstraZeneca’s Forxiga (dapagliflozin) ...

Read more →

Early benefit assessment reveals weaknesses in the development of new drugs

11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...

Read more →

Aimmune statement on ICER final report on AR101 for peanut allergy

11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...

Read more →

NICE recommends innovative treatment for type 1 diabetes

12 July 2019 - It’s estimated that around 90,000 people could be eligible for treatment with dapagliflozin. ...

Read more →

ICER publishes evidence report on treatments for Duchenne muscular dystrophy

11 July 2019 - No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive ...

Read more →

New drugs: where did we go wrong and what can we do better?

10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...

Read more →

ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks

10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...

Read more →

Institute for Clinical and Economic Review lists potential topics for assessments in 2020

9 July 2019 - The Institute for Clinical and Economic Review has released its preliminary list of potential assessment topics ...

Read more →

NICE Onpattro approval puts Alnylam back in hATTR running

 9 July 2019 - NICE has recommended the use of Alynylam’s Onpattro (patisiran), after issuing a preliminary ‘no’, back in ...

Read more →

New treatment approved for patients with breast cancer in Scotland

8 July 2019 - A new drug for patients with advanced breast cancer has been approved for use by the ...

Read more →

SMC - July 2019 decisions

8 July 2019 - A medicine used to treat advanced breast cancer has today been accepted by the Scottish Medicines ...

Read more →